Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000486783 | SCV000574108 | uncertain significance | not provided | 2020-05-26 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Labcorp Genetics |
RCV000537873 | SCV000640690 | likely benign | Nemaline myopathy 2 | 2024-01-29 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002525967 | SCV003629100 | uncertain significance | Inborn genetic diseases | 2021-09-17 | criteria provided, single submitter | clinical testing | The c.16561T>A (p.S5521T) alteration is located in exon 119 (coding exon 117) of the NEB gene. This alteration results from a T to A substitution at nucleotide position 16561, causing the serine (S) at amino acid position 5521 to be replaced by a threonine (T). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Revvity Omics, |
RCV000486783 | SCV003812809 | uncertain significance | not provided | 2023-12-19 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV000537873 | SCV001460595 | uncertain significance | Nemaline myopathy 2 | 2020-01-17 | no assertion criteria provided | clinical testing |